Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

Abstract Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are standard-of-care second-line therapies for relapsed or refractory large B-cell lymphomas, yet clinical and immunological predictors of durable benefit remain poorly defined. Here, we retrospectively analyze 64 pat...

Description complète

Détails bibliographiques

Auteurs principaux:	Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho, Victor Babatunde, Bianca Ho, Pooja Devi, Elise A. Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael R. Cook, Nasheed M. Hossain, Colin J. Thomas, Vrutti Patel, Vitor B. de Souza, Mohannad H. Alkhatib, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Antonio Imparato, Alberto Carturan, Patrizia Porazzi, Joseph A. Fraietta, Stephen J. Schuster, Ivan Maillard, Marco Ruella, Daniel J. Landsburg
Format:	Artigo
Langue:	Inglês
Publié:	Nature Portfolio 2026-05-01
Collection:	Nature Communications
Accès en ligne:	https://doi.org/10.1038/s41467-026-71710-7
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!